Running time: 21 minutes, 42 seconds
01.53 Cardiovascular kidney metabolic syndrome
02.44 Subclinical inflammation and cardiovascular risk
03.38 Latest data from EAS: Semaglutide, C-reactive
protein level and cardiovascular outcomes
05.56 Targeted anti-inflammatory therapies for CVD reduction
07.08 Effect of lipid lowering treatments on CRP levels
08.42 Facets of inflammation in acute MI
10.53 Genetic risk, LDL, lifestyle modifications and genetic tests
14.45 Cholesterol, plasma triglycerides, cardiovascular
and non-cardiovascular mortality
16.01 Novel tools to reduce triglyceride levels –
Zodasiran and Plozasiran
17.42 Lipoprotein(a)- a risk factor for ASCVD
20.44 Lp(a) lowering therapies